Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
Eric McDade, DO, Guoqiao Wang, PhD, Brian A. Gordon, PhD, Jason Hassenstab, PhD, Tammie L.S. Benzinger, MD, Virginia Buckles, PhD, Anne M. Fagan, PhD, … Show All … , David M. Holtzman, MD, Nigel J. Cairns, PhD, Alison M. Goate, PhD, Daniel S. Marcus, PhD, John C. Morris, MD, Katrina Paumier, PhD, Chengjie Xiong, PhD, Ricardo Allegri, MD, Sarah B. Berman, MD, William Klunk, MD, James Noble, MD, John Ringman, MD, Bernardino Ghetti, MD, Martin Farlow, MD, Reisa A. Sperling, MD, Jasmeer Chhatwal, MD, Stephen Salloway, MD, Neill R. Graff-Radford, MD, Peter R. Schofield, MD, Colin Masters, MD, Martin N. Rossor, MD, Nick C. Fox, MD, Johannes Levin, MD, Mathias Jucker, PhD, and Randall J. Bateman, MD for the Dominantly Inherited Alzheimer Network Show FewerAuthors Info & Affiliations
Abstract
Objective
To assess the onset, sequence, and rate of progression of comprehensive biomarker and clinical measures across the spectrum of Alzheimer disease (AD) using the Dominantly Inherited Alzheimer Network (DIAN) study and compare these to cross-sectional estimates.
Methods
We conducted longitudinal clinical, cognitive, CSF, and neuroimaging assessments (mean of 2.7 [±1.1] visits) in 217 DIAN participants. Linear mixed effects models were used to assess changes in each measure relative to individuals' estimated years to symptom onset and to compare mutation carriers and noncarriers.
Results
Longitudinal β-amyloid measures changed first (starting 25 years before estimated symptom onset), followed by declines in measures of cortical metabolism (approximately 7–10 years later), then cognition and hippocampal atrophy (approximately 20 years later). There were significant differences in the estimates of CSF p-tau181 and tau, with elevations from cross-sectional estimates preceding longitudinal estimates by over 10 years; further, longitudinal estimates identified a significant decline in CSF p-tau181 near symptom onset as opposed to continued elevations.
Conclusion
These longitudinal estimates clarify the sequence and temporal dynamics of presymptomatic pathologic changes in autosomal dominant AD, information critical to a better understanding of the disease. The pattern of biomarker changes identified here also suggests that once β-amyloidosis begins, additional pathologies may begin to develop less than 10 years later, but more than 15 years before symptom onset, an important consideration for interventions meant to alter the disease course.
Get full access to this article
View all available purchase options and get full access to this article.
Publication history
Received by Neurology August 22, 2017. Accepted in final form July 5, 2018.
References
1.
Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.
2.
Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol2013;169:737–743.
3.
Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 2015;72:316–324.
4.
Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease: a longitudinal prospective study. Brain 1998;121:1631–1639.
5.
Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048–1056.
6.
Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis 2012;30:847–856.
7.
Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85–92.
8.
Cash DM, Ridgway GR, Liang Y, et al. The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology 2013;81:1425–1433.
9.
Chhatwal JP, Schultz AP, Johnson K, et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology 2013;81:736–744.
10.
Ringman JM, Liang LJ, Zhou Y, et al. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain 2015;138:1036–1045.
11.
Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 2014;28:19–29.
12.
Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347–1358.
13.
Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014;83:253–260.
14.
Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs13.
15.
Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl 3):321–329.
16.
Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Invest 2012;2:975–984.
17.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.
18.
Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement 2017;13:8–19.
19.
Benzinger TL, Blazey T, Jack CR Jr, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 2013;110:E4502–E4509.
20.
Su Y, D'Angelo GM, Vlassenko AG, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One 2013;8:e73377.
21.
Su Y, Blazey TM, Owen CJ, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer's disease: results from the DIAN study group. PLoS One 2016;11:e0152082.
22.
Cleveland WS, Devlin SJ, Grosse E. Regression by local fitting: methods, properties, and computational algorithms. J Econom 1988;37:87–114.
23.
Jack CR, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81:1732–1740.
24.
Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357–367.
25.
Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 2016;139:1226–1236.
26.
Palmqvist S, Schöll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8:1214.
27.
Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014;6:226ra30.
28.
Yamada K, Cirrito JR, Stewart FR, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 2011;31:13110–13117.
29.
Potter R, Patterson BW, Elbert DL, et al. Increased in vivo Amyloid-Beta 42 production, exchange, and irreversible loss in presenilin mutations carriers. Sci Transl Med 2013;5:189ra77.
30.
Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol 2013;126:659–670.
31.
Sutphen CLML, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM. Longitudinal decrease in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer disease. Alzheimers Dement 2018;14:869–879.
32.
Jack CR, Wiste HJ, Knopman DS, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014;82:1605–1612.
33.
Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 2018;17:241–250.
Information & Authors
Information
Published In
Copyright
© 2018 American Academy of Neurology.
Publication History
Received: August 22, 2017
Accepted: July 5, 2018
Published online: September 14, 2018
Published in print: October 2, 2018
Permissions
Request permissions for this article.
Disclosure
E. McDade: Elli Lilly scientific advisory board, UpToDate. G. Wang and B. Gordon report no disclosures relevant to the manuscript. J. Hassenstab: Biogen (consultant), Lundbeck (consultant). T. Benzinger and V. Buckles report no disclosures relevant to the manuscript. A. Fagan: Roche Diagnostics (advisory board), IBL international (advisory board), DiamiR (consultant), AbbVie (consultant), Genentech (advisory board). D. Holtzman and N. Gairnes report no disclosures relevant to the manuscript. A. Goate: royalties from Taconic and Athena Diagnostics; personal fees from Denali Therapeutics, AbbVie. D. Marcus, J. Morris, K. Paumier, C. Xiong, R. Allegri, and S. Berman report no disclosures relevant to the manuscript. W. Klunk: GE Healthcare holds a license agreement with the University of Pittsburgh based on the PiB PET technology described in this manuscript. Dr. Klunk is a coinventor of PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. The other authors have no conflicts of interest based on PiB PET and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. J. Noble, J. Ringman, B. Ghetti, and M. Farlow report no disclosures relevant to the manuscript. R. Sperling: personal fees from Avid/Lilly, personal fees from Janssen Immunotherapy, personal fees from Bracket, personal fees from Genentech, personal fees from Sanofi, personal fees from Roche, personal fees from AbbVie, personal fees from Lundbeck, personal fees from Otsuka, personal fees from Merck, outside the submitted work. J. Chhatwal, S. Salloway, N. Graff-Radford, P. Schofield, C. Masters, and M. Rossor report no disclosures relevant to the manuscript. N. Fox: personal fees from Janssen, personal fees from Roche, personal fees from Lilly, personal fees from Novartis, personal fees from GSK, personal fees from Biogen, outside the submitted work and paid to UCL. J. Levin: personal fees from Aesku, personal fees from Bayer Vital, personal fees from Willi Gross Foundation, outside the submitted work. M. Jucker and R. Bateman report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
Study Funding
Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, UF1 AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), the Raul Carrea Institute for Neurological Research (FLENI), the MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1), and NIHR Queen Square Dementia Biomedical Research Unit. This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. The corresponding authors had full access to the data in the study and had final responsibility for the decision to submit for publication.
Authors
Affiliations & Disclosures
Eric McDade, DO
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Eli Lilly
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
T-018562- Cerebrospinal fluid (CSF) Tau Rate of Phosphorylation Measurement to Define Stages of Alzheimer?s Disease and Monitor Brain Kinases/Phosphatases Activity
Publishing Royalties:
1.
Mild Cognitive Impairment I and II, UpToDate Inc., 2010- 2018.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
K23AG046363 (PI)-Cerebrovascular Reactivity in the Presence of Cerebral Amyloid and Cerebrovascular Disease: A novel multi-modal imaging measure of vascular reserve in cognitively normal elderly 5U01 AG032438 (PI Bateman, R) NIH/NIA- Dominantly Inherited Alzheimer Network; Site PI.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1. GHR, 2. Anonymous Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Guoqiao Wang, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Brian A. Gordon, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
I performed neuropsychological testing for a clinical trial of AV-1451 for Avid Radiopharmaceuticals
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIA, K01 AG053474, PI, 2017-2018 (2) NIA, P01AG026276, collaborator, 2014-2017 (3) NIA, P50AG005681, collaborator, 2017-2017 (4) NIA, UF1AG032438, collaborator, 2014-2017 (5) NINDS, P01NNS080675, collaborator, 2016-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jason Hassenstab, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
1. Advisory board member for Biogen. 2. Advisory board member for Lundbeck.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1. Consultant for Biogen. 2. Consultant for Lundbeck. 3. Consultant for Pfizer.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. UF1 AG032438 09/15/08 - 12/30/19, Co-Investigator 2. U01 AG042791 09/20/13 ? 6/30/19, Co-Investigator 3. R01 AG046179 08/01/14 ? 12/31/19, Co-Investigator 4. R56 AG053267 09/30/16 ? 08/31/20, Co-Investigator 5. P50 AG005681 05/01/15 ? 04/30/20, Co-Investigator 6. P01 AG003991 08/15/14 ? 4/30/19, Co-Investigator 7. P01 AG026276 09/30/16 - 5/31/21, Co-Investigator 8. 1R01AG053548 07/01/17 - 06/30/22, Co-Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Tammie L.S. Benzinger, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) National Multiple Sclerosis Society, travel to grant review (2) Radiologic Society of North America, travel to grant review (3) Alzheimer's Disease - Parkinsons' Disease Meeting 2017, travel (invited speaker) (4) Alzheimer's Association International Convention (AAIC) 2017, travel (invited speaker) (5) Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2017, travel (invited speaker)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Unpaid consulting, ADMDx
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Investigator initiated research grants, Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Support for the research projects only, no personal compensation or salary support. (2) Roche - participation as site investigator in clinical trials (3) Biogen - participation as site investigator in clinical trials (4) J&J - participation as site investigator in clinical trials (5) Lilly - participation as site investigator in clinical trials
Research Support, Government Entities:
1.
(1) 5P01AG026276 (PI: J. Morris) 10/1/11-9/30/15 NIH/NIA Adult Children Study (ACS) Role: Project 4 Principal Investigator (T. Benzinger) (2) 1 U01AG032438 (PI: J. Morris) 9/30/08-6/30/14 NIH/NIA Dominantly Inherited Alzheimer Network (DIAN) Role: Core G (Imaging Core) Principal Investigator (T. Benzinger) (3) AG003991-27 (PI: J. Morris) 5/15/09?12/31/13 NIH/NIA HASD: Healthy Aging and Senile Dementia, Imaging Core (Core Director, T. Benzinger) (4) 1R01 NS066905-01 (PI: D. Marcus) 9/30/09 ? 6/30/2014 NIH/NINDS BIRN Resources Facilitate the Personalization of Malignant Brain Tumor Role: Co-Investigator (5) 1R01 AG043434 (PI: C. Roe) 9/30/12-8/31/17 NIH Title: Driving Performance in Preclinical Alzheimer?s Disease Role: Co-investigator (6) 1P01NS059560-01A1 (PI: A. Cross) 10/1/2008 ? 7/31/12 NIH/NINDS Title: Biomarkers and Pathogenesis of MS: From Mouse to Human Role: Co-Investigator (7) Research Grant 6/01/10 ? 6/31/12 Washington University Institute of Clinical and Translational Science, UL1 RR024992 Title: qBOLD MR measurements of oxygen extraction fraction in patients with brain tumors Role: Project PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Barnes-Jewish Hospital Foundation (2) Foundation for the ASNR (3) Hope Center (4) Alzheimer's Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Virginia Buckles, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH/NIA, U01AG026276, Investigator, 09/30/16 - 05/31/21 (2) NIH/NIA, P01AG003991, Investigator, 08/15/14 ? 04/30/19 (3) NIH/NIA, P50AG005681, Investigator, 05/01/15 ? 04/30/20 (4) NIH/NIA, UF01AG032438, Investigator, 07/16/14 - 06/30/19 (5) NIH/NIA, P01AG052350, Investigator, 09/30/16 - 10/01/21
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anne M. Fagan, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Advisory Board: 1) Roche Diagnostics 3) AbbVie 4) Genentech There are no conflicts of interest
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
1) 6,465,195 B2 10/15/2002 Predictive diagnostic for Alzheimers disease David Holtzman, Anne Fagan Niven, Steve Younkin, Linda Younkin 2) PCT/US09/050255 (7/10/2009, in process) A risk factor and new therapeutic target for Alzheimers disease Alison Goate, Carlos Cruchaga, David Holtzman, Anne Fagan Niven
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1) DiamiR 2) LabCorp 3) Araclon Biotech/Griffols 4) Fujirebio
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1) Roche Diagnostics Research Grant 2) Biogen Research Grant 3) Fujirebio Research Grant
Research Support, Government Entities:
1.
5R01AG046179-03 08/01/14 ? 12/31/19 NIH/NIA Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial. Role: Component Leader 2UF1AG032438-07) 09/15/08 ? 12/31/19 NIH/NIA Dominantly Inherited Alzheimer Network (DIAN); Biomarker Core. Role: Biomarker Core Leader 5R01AG045611-03 05/01/14 ? 02/28/19 NIH/NIA Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration. Role: Co-Investigator P01AG003991 01/01/97 ? 04/30/19 NIH/NIA Healthy Aging and Senile Dementia; Project 2: Potential Prognostic and Theranostic Markers for Preclinical AD. Role: Co-Investigator for Project 2 5U01AG051406-02 09/30/15 ? 04/30/20 NIH/NIA Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease. Role: Co-Investigator P50AG005681 09/30/85 ? 04/30/20 NIH/NIA Alzheimer?s Disease Research Center; Project 1 Role: Leader of Project 1 2R01AG038791-06A1 03/01/16 ? 02/28/21 NIH/NIA The Four Repeat Tauopathy Neuroimaging Initiative. Role: Co-Investigator P01AG026276 07/01/05 ? 05/31/21 NIH/NIA Antecedent biomarkers for AD: The Adult Children Study; Biomarker Core. Role: Leader of Biomarker Core P01AG026276 07/01/05 ? 05/31/21 NIH/NIA Antecedent biomarkers for AD: The Adult Children Study; Project 2. Role: Leader of Project 2 P01AG052350 9/30/16 ? 05/31/21 NIH/NIA Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's Disease. Role: Co-Investigator RF1AG053550 09/01/16 ? 06/30/21 NIH Antecedent Biomarker Changes in AD: Ordering, Stages, and Implications for Trials. Role: Co-Investigator R01AG054513-01A1 07/01/17 - 04/30/22 NIH/NIA In vivo MRI Biomarkers of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease. Role: Co-Investigator R01AG053267-01A1 09/31/16 ? 5/31/22 NIH DIAN-TU Next Generation Prevention Trial. Role: Component Leader R01AG056466-01 08/01/17 - 05/31/22 NIH/NIA Preclinical Alzheimer Disease and Driving. Role: Co-Investigator 1R01AG054567-01A1 09/15/17 ? 06/30/22 NIH/NIA Quantification of Neuroinflammation in Alzheimer's Disease Using Diffusion Basis Spectrum Imaging. Role: Co-Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David M. Holtzman, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Commercial entities,
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
1. Science Translational Medicine, editorial advisory board member 2. Journal of Experimental Medicine, editorial advisory board member 3. Annals of Neurology, editorial advisory board member
Patents:
1.
1) Antibodies to tau, Pub App no. 20150183855. Patent describes production and potential use of anti-tau antibodies. 2) Compositions and methods for treating amyloid plaque associated symptoms, Pub App no. 20160355581. Patent associated with development of anti- apoE antibodies for potential therapeutic use. 3) Methods of determining amyloid beta turnover in blood, Pub App no. 20170146557. Patent associated with measurement of labeled and unlabeled Abeta peptides in the blood as a potential diagnostic.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1. Eli Lilly 2. Genentech 3. AbbVie
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
1. C2N Diagnostics, LLC. Co-founder with equity. Company focuses on development of diagnostics for Alzheimer disease.
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1. C2N Diagnostics, research grant to my lab at Washington University. 2. AbbVie, research grant to my lab at Washington University. 3. Eli Lilly, research grant to my lab at Washington University. 4. Denali, research grant to my lab at Washington University.
Research Support, Government Entities:
1.
1. NIH-NINDS- NS090934, role P.I., Period of award: 8/1/14-3/31/19 2. NIH-NIA-AG047644, role P.I. Period of award, 8/15/14- 4/30/19 3. NIH-NIA-AG048678, role co-P.I., Period of award 8/1/15-3/31/20 4. NIH-NINDS- 1P01NS074969, role P.I. Period of award: 8/1/17-6/30/22
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
1) Antibodies to tau, Pub App no. 20150183855. Patent describes production and potential use of anti-tau antibodies. Source of payment to Washington University, C2N Diagnostics 2) Compositions and methods for treating amyloid plaque associated symptoms, Pub App no. 20160355581. Patent associated with development of anti- apoE antibodies for potential therapeutic use. Source of payment to Washington University, Denali 3) Methods of determining amyloid beta turnover in blood, Pub App no. 20170146557. Patent associated with measurement of labeled and unlabeled Abeta peptides in the blood as a potential diagnostic. Source of payment to Washington University, C2N Diagnostics
Royalty Payments, Technology or Inventions:
1.
1. Humanized Antibodies that Sequester ABeta Peptide, US patent number 7,195,761. rights to potential future royalty payments, Eli Lilly to Washington University
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nigel J. Cairns, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
I am on the editorial board of Brain Pathology.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Support for this work was provided by grants from the NIH (National Institute on Aging, P50-AG05681 and P01- AG03991), and the Charles Knight Fund.
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alison M. Goate, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Denali Therapeutics (2) Pfizer (3) DZNE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1. Rainwater Foundation 2014-2018 travel to attend meeting 2. Indiana University ADRC advisory board 2015, 2016 3. Wellcome Trust 2018 travel to attend meeting
Editorial Boards:
1.
eLife, reviewing editor
Patents:
1.
PSEN mutations in AD Tau mutations in FTD TDP43 mutations in ALS\FTD
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1. Cognition Therapeutics 2015 2. AbbVie 2016 3. Biogen 2018
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
F Prime
Research Support, Government Entities:
1.
1. NIA 1R01AG035083- (Goate) PI 9/1/10-8/31/15 2. NIA 1U01AG032984-01 (Schellenberg\Goate) Co- Investigator/Core Director 4/1/09-3/31/14 3. NIA U01 AG049508-01 Goate (PI) 6/11/14-5/31/18 4. NIA R01 AGO41797-03 Goate Site PI 4/1/12-3/13/17 5. NIA U01 AG052411 Goate (PI) 8/1/2016-7/31/2020 6. NIA RF1AG05401 Goate (PI) 08/01/16-06/30/21 7. NIA 5U01AG032438-07 (Morris) Co-Investigator/Core Director 9/15/08-6/30/19 8. NIAAA 5U10AA08401-25 (Goate/ site PI) Co-Investigator 9/29/89-8/31/19
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1. Rainwater Charitable Foundation 2. JPB Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
1. Taconic Industries for tau mutation patent 2. Athena Diagnostics TDP43 mutation testing
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Daniel S. Marcus, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Frontiers in Neuroinfromatics
Patents:
1.
(1) Patent pending (U.S. Patent Application Serial No. 12/634,392) for a software system to select and perform automated medical imaging analysis
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
(1) Radiologics, Inc. President, 2017-2018
Consultancies:
1.
(1) Avid Radiopharmaceuticals, Inc.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Medtronic (2) Elekta (3) White Rabbit
Research Support, Government Entities:
1.
(1) Department of Defense, Investigator (2) NIH, U24 RR025736, Site PI (3) NIH, U01 AG032438-019008, Investigator (4) NIH, R01 MH074916, Investigator (5) NIH, P01 AG026276, Investigator (6) NIH, U54 EB005149, Investigator (7) NIH, P30 NS048056, PI (8) NIH, R01 EB009352, PI (9) NIH, R01 NS066905, PI Stock/Stock Options, Medical Equipment & Materials: (1) White Rabbit, 2017-2018 (2) Radiologics, 2009-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John C. Morris, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Lilly USA
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
serves on the editorial advisory board of JAMA Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
Blackwell publishing Taylor & Francis
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Lilly USA
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
receives research support from Eli Lilly/Avid Radiopharmaceuticals
Research Support, Government Entities:
1.
National Institute on Aging grants P50AG005681; P01AG003991; P01AG026276; UF01AG032438
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
1. Clinical Dementia Rating assessment tool (pharma-sponsored clinical trials of investigational drugs for Alzheimer disease 2. AD8 assessment tool (pharma-sponsored clinical trials of investigational drugs for Alzheimer disease)
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Katrina Paumier, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
I currently work for UCB Pharmaceuticals. I have been employed at UCB for 6 months as a Medical Science Liaison
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Alzheimer's disease CSF Tau Isoforms Stable Isotope Labeling Kinetics (SILK); 15% Effort Principal Investigator: Randall J. Bateman Agency: Tau Silk/PET Pharma Consortium Type: Investigator Initiated Research Period: 2/3/2016- 1/31/2018 We will measure TAU Pathology by PET scan and tau isoforms kinetics in human CNS in AD and age-matched controls. 16 additional AD and 16 additional age-matched controls will be enrolled for 10 days of oral labeling, followed by 5 lumbar punctures for each participant to collect CSF. CSF will be analyzed for total tau production and clearance. Institution will use the pre- existing labeled human CSF samples used to study the total tau kinetics, the CSF collected from participants who have been orally labeled for 10 days with 13C6- leucine. This will be the first time measuring the kinetics of human tau isoforms and will establish a unique tool for elucidating the pathophysiology of AD and other tauopathies.
Research Support, Government Entities:
1.
Dominantly Inherited Alzheimer Network (DIAN); 40% Effort Principle Investigator: Randall J. Bateman Agency: National Institutes of Health Type: U01AG032438 ? Core A Period: 1/1/13- 12/31/19 DIAN is an international study of autosomal dominantly inherited Alzheimer?s disease. The aims of the study are to create a registry of pedigree with known AD causing mutations and to measure clinical and psychometric performance with imaging, CSF, and blood biomarkers. Dominantly Inherited Alzheimer's Network Trial Unit - Adaptive Prevention Trial (APT); 10% Effort Principal Investigator: Randall J. Bateman Agency: National Institutes of Health Type: R1AG046179-01 Period: 8/1/2014 ? 4/30/2019 The proposed grant will initiate a phase 3 cognitive end- point prevention trial of an anti-Aβ drug in individuals with known causative mutations for dominantly inherited Alzheimer?s disease (AD) which is rare and the symptoms and brain changes are similar to those observed in the more common late-onset sporadic AD. The results of the trial may lead to approval and registration of a drug for the prevention of dominantly inherited AD. CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease; 15% Effort Program Director: Randall J. Bateman Agency: NIH/NINDS Type: R01NS065667 Period: 08/01/2012-07/31/2017 Genetic, biochemical, and animal model studies suggest the accumulation and conformational change of amyloid- beta (Aβ) is a major contributor to the pathogenesis of AD. To determine if increased synthesis, decreased clearance or both are associated with AD, we will measure Aβ production and clearance rates in sporadic AD versus controls. We will determine if ApoE4 is associated with decreased Aβ clearance. This study will provide the first measurements of Aβ synthesis and clearance in Alzheimer?s disease and measure the effect of the major genetic risk factor in humans (APOE).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Development of a Technique to Measure Alpha-Synuclein Kinetics In Vivo; 15% Effort Principal Investigator: Paul Kotzbauer Agency: Michael J. Fox Foundation Type: Staff Directed Application Period: 12/15/2015-03/2017 To advance the development of α-syn therapeutics, we propose to develop a Stable Isotope Labeling Kinetics (SILK) technique to measure α-syn kinetics in human cerebral spinal fluid (CSF).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Chengjie Xiong, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NIA UF1AG032438, Biostatistics Core leader
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ricardo Allegri, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Teva, Gador, Biogen as Speaker honorarias (Honoraria for speaking engagements)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Sponsor: CONICET (Consejo Nacional de Investigaciones Cient?ficas y tecnol?gicas, Argentina), grant: PICT 2015-2110, Rol Principal Investigator. Years 2015-2019.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Sponsor: FLENI Foundation (Fundacion de Lucha contra enfermedades neurol?gicas, Argentina).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sarah B. Berman, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) NIH, 3UF1AG032438, Dominantly Inherited Alzheimer Network (DIAN) Longitudinal Study, site-PI, 2015-2018 2) NIH DIAN-TU-001, site-PI,2015-18 3) NIH R01NS077964, PI, 2012-2017 4) NIH R01NS101628, co-investigator, 2017-2022. 5) NIH R01ES022644, co-investigator, 2013-2018
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
UPP Academic Foundation Research grant, University of Pittsburgh
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
William Klunk, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Biogen DSMB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
(1) PiB PET Imaging, US 7,270,800 (plus related), issued 2007 (2) Chrysamine-G Derivatives for imaging and therapy, US 6,168,776 (plus related), issued 2001
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
(1) Research (not clinical) PiB PET imaging (0% clinical), 2003-present.
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIA, RF1 AG025516, PI 2005-2019 (2) NIA, P01 AG025204, PI 2005-2021 (3) NIA, P50 AG005133, co-Investigator 2005-2020 (4) NIA/NICHD U01 AG051406, Multiple PI 2015-2020
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Michael J Fox Foundation, co-I 2010-2016 (2) Pittsburgh Foundation, co-I 2013-15
Stock/stock Options/board of Directors Compensation:
1.
(1) Cognoptix, Inc., hold stock, 2007-present
License Fee Payments, Technology or Inventions:
1.
(1) PiB PET Imaging, GE Healthcare, 2002-present
Royalty Payments, Technology or Inventions:
1.
(1) PiB PET Imaging, GE Healthcare, 2002-present
Stock/stock Options, Research Sponsor:
1.
(1) Cognoptix, Inc., 2007-present
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
James Noble, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Reimbursement for travel expenses for the Big 10/Ivy league concussion summit - scientific collaboration annual meeting
Editorial Boards:
1.
NONE
Patents:
1.
I am involved with development a real-time concussion diagnostic tool. I am unable to disclose the intellectual property but do not appreciate a conflict of interest with this manuscript.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH: U54 NS081765 (Co-I), R01 NS067443 (Co-I), R01AG054536 (PI), T35 AG044303 (Co-PI). None of these directly supported this work, nor are they relevant.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Stock options: Bats Toi wrestling headgear (not a concussion tool/diagnostic). I do not appreciate a conflict of interest with this manuscript.
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John Ringman, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1) Pfizer 2) Elan Pharmaceuticals 3) Bristol Meyers Squibb 4) Eli-Lilly Pharmaceuticals 5) Hoffman LaRoche 6) Merck Pharmaceuticals
Research Support, Government Entities:
1.
1) Dr. Ringman received research support from an Alzheimer's Disease Research Center Grant (AG016570), 2010-2015, Clinical Core Leader 2) Dr. Ringman received research support for the Dominantly Inherited Alzheimer Network (AG-032438) from the National Institute on Aging, 2008-2015, Site PI 3) Dr. Ringman receives research support for the Dominantly Inherited Alzheimer Network (AG-032438) from the National Institute on Aging, 2015-Present, Site Investigator 4) Dr. Ringman receives research support from AG-052350 from the National Institute on Aging, 2016-Present, Co-Investigator 5) Dr. Ringman receives research support from AG-051218 from the National Institute on Aging, 2015-Present, Co-Investigator 6) InnoSense, LLC, R44 AG046059-3 9/26/16 ? 4/30/18, NIH/NIA Co-Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarker Development
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bernardino Ghetti, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel honoraria from Piramal Imaging. Speaker honorarium from Eli Lilly UCSD
Editorial Boards:
1.
Brain Pathology, member editorial board, 2006 Prion, member editorial board,2006 American Journal of Neurodegenerative disease,member editorial board, 2012
Patents:
1.
1) Alzheimer disease transgenic mouse
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1) Piramal 2) Eli Lilly
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Eli Lilly
Research Support, Government Entities:
1.
1) NIA, PHS P30AG010133 2) NIA/NINDS PHS R13AG038256
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) Alzheimer's Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Martin Farlow, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Accera, Avanir, Axovant, AZ Therapies, Cognition Therapeutics, Eli Lilly & Company, FORUM Pharmaceuticals, INC Research, KCRN Research, Kyowa Kirin Pharma, Longeveron, Medavante, Merck and Co. Inc., Proclara (formerly Neurophage Pharmaceuticals), Neurotrope Biosciences, Otsuka Pharmaceutical, Stemedica Cell Technologies, Inc., Takeda, United Neuroscience Inc., vTv Therapeutics
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
MedLink Online Publications 2002-Present, Editor
Patents:
1.
Method and Animal Model for AD, Patent, Co-Inventor
Publishing Royalties:
1.
Annual Epidemiology, pathology and pathogensis of dementia with Lewy bodies. Published by UptoDate. Continously gets updated.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
AbbVie, Accera, ADCS Posiphen, Biogen, Eisai, Eli Lilly, Genentech, Roche, Lundbeck, Chase Pharmaceuticals, Boehringer Ingelheim, Novartis, Suven Life Sciences, Ltd.
Research Support, Government Entities:
1.
NIH/NIA (ADCS Studies), AD Lahiri Grant, Boustani Grant and Foroud Grant.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
PdP Mouse Model Stock/Stock Options, Medical Equipment & Materials: MedAvante (options)
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Reisa A. Sperling, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial - Lundbeck Commercial - Insightec Commercial - Pfizer Commercial - Eisai Commercial - Roche
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Personal: 1) Biogen, commercial 2) Roche, commercial 3) Lundbeck, commercial, 4) Merck, commercial, 5) Insightec, commercial, 6)Roche, commercial, 7) Pfizer, commercial, 8) General Electric, commercial, 9) AC Immune, commercial, 10) Eisai, commercial Spouse: 1)Lundbeck, commercial 2) Piramal Healthcare, commercial, 3) Siemens, commercial 4) Novartis
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Janssen - clinical trial support 2016-present Eli Lilly- clinical trial support 2014-present
Research Support, Government Entities:
1.
1) National Institute on Aging P01AG036694, principal investigator, 2010-2020; 2) National Institute on Aging P50AG005134, 2009-2020; 3) National Institute on Aging U19 AG10483, Projet Leader A4 trial, 2012-2018.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer's Association, co-principal investigator, 2016-2020.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jasmeer Chhatwal, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) non-profit: Dominantly Inherited Alzheimer's Network Treatment Unit (DIAN-TU), therapeutics evaluation committee
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH K23 AG049087, PI, 2015-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) American Brain Foundation / American Academy of Neurology Clinical Research Training Fellowship (2) BrightFocus Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Stephen Salloway, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Avid-Lilly scientific advisory board Roche scientific advisory board Merck scientific advisory board Novartis scientific advisory board Genentech scientific advisory board All < $5,000
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Novartis, travel, honoraria Roche, consulting Global Alzheimer's Platform, travel Lilly, consulting
Editorial Boards:
1.
Journal of Alzheimer's Prevention 2014-2015, Alzheimer?s and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015
Patents:
1.
NONE
Publishing Royalties:
1.
American Psychiatric Press Inc-The Frontal Lobes and Neuropsychiatric Illness and The Neuropsychiatry of Limbic and Subcortical Disorders Humana Press-Vascular Dementia
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NIA-ADNI DIAN A4 ACTC Eisai Novartis
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The Norman and Rosalie Fain Family Foundation The Alzheimer's Association Joukowsky Family Foundation Winter Family Rhode Island Foundation Global Alzheimers Platform Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Neill R. Graff-Radford, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
1) Alzheimer Disease and Therapy, Editorial Board
Publishing Royalties:
1.
I received royalties for an article in UpToDate
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1)Novartis multicenter study, (2) Lilly multicenter study, (3) Biogen multicenter study, (4) Axovant multicenter study
Research Support, Government Entities:
1.
(1) NIA P50AG16574 coinvestigator ADRC; (2) NIA U24AG26395 Site PI LOAD study; (3) NIA U01AG24904 Site PI ADNI; (4) NIA R01AG06656 Coinvestigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Peter R. Schofield, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Jannsen-Cilag Australia, Speaker Fee.
Editorial Boards:
1.
(1) Psychiatric Genetics, Editorial Board member, 2002 - present, (2) Australian and New Zealand Journal of Psychiatry, International Advisory Board member, 2011 - present, (3) International Journal of Neuropsychopharmacology, Editorial Board member, 2011 - present.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
ICMI Australian Professional Speakers Bureau
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
This study (1) NIH Grant 1U01 AG032438-01, Site Investigator, 2008-2014, (2) NIH Grant UF1AG032438, Site Investigator, 2014-2019, Other research support (3) NHMRC (Australia) Program Grant 1037196, Chief Investigator, 2013-2017, (4) NHMRC Project Grant, 1005769, Chief Investigator, 2011-2013, (5) NHMRC Enabling Grant, 401184, Chief Investigator, 2006-2012, (6) NHMRC Project Grant, 568807, Chief Investigator, 2009-2012, (7) NHMRC Project Grant, 630574, Chief Investigator, 2010-2012, (8) NHMRC Project Grant, 1023202, Chief Investigator, 2012-2014, (9) Australian Research Council Linkage Grant LP0883261, Chief Investigator, 2008-2012, (10) NIH Grant 1R01 NS052470-01A2, Subcontractor, 2007-2012, (11) NHMRC/ARC Program Grant, 401162, Chief Investigator, 2007-2011, (12) NHMRC CCRE Grant, 455431, Chief Investigator, 2007-2011, (13) Australian Research Council Linkage Grant LP120200075, Chief Investigator, 2012-2015, (14) NHMRC Project Grant, 1063960, Chief Investigator, 2014-2016.
Research Support, Academic Entities:
1.
(1) University of New South Wales.
Research Support, Foundations and Societies:
1.
(1) Beyondblue National Priority Driven Research Project Grant, (2) Wicking Trust Grant #20821, (3) Wicking Trust Grant #13026, (4) Mason Foundation Grant #CT21919, (5) Rebecca Cooper Medical Research Foundation Equipment Grant.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Colin Masters, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Martin N. Rossor, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editorial Board member of: Dementia and Geriatric Cognitive Disorders (2002-date) Neurodegenerative Diseases (2002 to date) Alzheimer?s Research & Therapy (2010 to date) Faculty of 1000 2010 to date) Editor Journal of Neurology Neurosurgery and Psychiatry, (2004-2009)
Patents:
1.
NONE
Publishing Royalties:
1.
Queen Square Textbook - royalties paid to hospital
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultancy fees as an adviser for Merck. These are paid to the Institution and not to Martin Rossor personally
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIHR National Director for Dementia Research (2014 to date)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nick C. Fox, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Payments were made to University College London (1) Biogen (2) Roche
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) GE Healthcare
Editorial Boards:
1.
(1) Alzheimer's Disease and Associated Disorders, Editorial Board Member, 2004 to present; No compensation (2) Neurodegenerative Diseases, Editorial Board Member, 2004 to present; No compensation (3) Alzheimer?s Research and Therapy, Editorial Board Member, 2008 to present; No compensation (4) Lancet Neurology, Editorial Board Member, 2014 to present; No compensation
Patents:
1.
(1) QA Box for automated checking of MRI scans; Filed 4 May 2007
Publishing Royalties:
1.
(1) Neuroimaging in Dementia, Springer, 2011
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Payments were made to University College London (1) Eli Lilly
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1)NIHR BRC award (Co-lead) (?5 million) 2017-2022 (2) MRC UK Dementia Research Institute (PI) (?600,000) 2017- 2022 (3) NIHR, Senior Investigator Award, 2009-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Wolfson Foundation, funding for the Leonard Wolfson Experimental Neurology Centre
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Johannes Levin, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Axon Neuroscience (2) Ionis Pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Bayer Healthcare (2) AbbVie
Editorial Boards:
1.
Journal of Aging and Gerentology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Aesku
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Hirnliga (2) LeJeune Foundation (3) Hirnliga
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mathias Jucker, PhD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
Synapsis Foundation, non-profit Plan Alzheimer, non-profit
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
BMBF Hertie Foundation
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
BMBF, EC(JPND)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Randall J. Bateman, MD
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) 2009-present Alzheimer?s disease Cooperative Study (ADCS - 5U01AG010483-20) Steering Committee Member representing Washington University (3) 2009-present National Alzheimer?s Disease Neuroimaging Initiative Industry Scientific Advisory Board Amyloid-β Subteam member (4) International Federation of Clinical Chemistry and Laboratory Medicine, CSF-Proteins Working Group Member (5) Roche (6) Merck (7) Pfizer
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Salk Institute for Biological Studies - Adler Meeting - travel. (2) Rainwater Foundation - Tau Consortium - travel (3) Rockefeller University - travel (4) Alzheimer's Association - travel (5) Merck - travel and honoraria (6) Duke - travel (7) Janssen - travel and honoraria (8) Alzheimer's Disease International - travel (9) Pfizer - travel and honoraria (10) Roche - travel and honoraria (11) AC Immune - travel and honoraria (12) MIT - travel (13) American Neurological Association - travel
Editorial Boards:
1.
(1) Alzheimer's Research and Therapy, Editorial Board 2009- present (2) The Journal for the Prevention of ALzheimer Disease, Editorial Board 2014-present
Patents:
1.
(1)Holtzman, DM, Bateman, RJ, Kim, J, inventors; Washington University in St. Louis, assignee. Methods for measuring the metabolism of CNS derived biomolecules in vivo. US Patent Application 12/267,974. June 4, 2009. (2)Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Fluctuations in Amyloid Beta as a Biomarker for Alzheimer?s Disease. US Patent Application PCT/US2008/086529. June 18, 2009. (3) Bateman, RJ, Wildsmith, KR, Dobrowolska, J, Munsell, L,Mawuenyega, K, inventors; The Washington University, assignee. Methods for simultaneously measuring the in vivo metabolism of two or more isoforms of a biomolecule. US Patent Application PCT/US2009/064146. May 20, 2010. US Patent Application 13/129,036. December 1, 2011. (4) Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Methods for Measuring the Metabolism of Neurally Derived Biomolecules in Vivo. US Patent 7,892,845. October 2, 2008. US Patent 8,232,107. July 31, 2012 US Patent Application 14/224,993. July 17, 2014. (5) Bateman, RJ, Holtzman, DM, Mawuenyega, K, inventors; The Washington University, assignee. Methods of determining amyloid beta turnover in blood. US Patent Application PCT/US2011/037754. June 26, 2012. US Patent Application 13/699,497. May 9, 2013. (6) Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Methods for Diagnosing Alzheimer?s Disease. US Patent Application PCT/US2012/070623. June 27, 2013 (7)Bateman, RJ, Patterson, BW, Elbert, DL, inventors; Washington University, assignee. Methods of Diagnosing Amyloid Pathologies Using Analysis of Amyloid-Beta Enrichment Kinetics. US Patent Application PCT/US2013/071042. May 30, 2014. (8) Bateman, RJ, inventor; Washington University, assignee. Plasma Based Methods for Detecting CNS Amyloid Deposition. US Patent Application 62/492,718. May 1, 2017. US Patent Application 62/515,294. June 5, 2017.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
(1) Washington University School of Medicine Charles F. and Joanne Knight Distinguished Professor of Neurology, 2012-present (2) A4, Site Principal Investigator, 2014 to present (3) Washington University School of Medicine, Professor of Neurology, 2015 (4) Dominantly Inherited Alzheimer?s Network Trials Unit (DIAN-TU), Director, 2011-Present (5) Dominantly Inherited Alzheimer's Network (DIAN), Director, 2013-present
Consultancies:
1.
(1) Roche (2) Merck (3) Pfizer
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Eli Lilly (2) Roche (3) Janssen (4) DIAN Pharmaceutical Consortium (5) Abbvie (6) Avid
Research Support, Government Entities:
1.
(1) NIH R13AG055232, PI, 2016 (2) NIH R01AG053798, Advisor, 2017-present (3) NIH R01NS095773, PI, 2016-present (4) NIH/NIA U01AG042791, PI, 2013-present (5) NIH/NIA R01AG046179, PI, 2014-present (6) NIH/NIA UF1AG032438, PI, 2008-present (7) NIH R01AG053267, PI, 2017-present (8) NIH R56AG053267, PI, 2016-2017 (9) NIH U19AG010483, Site PI, 2012-present (10) NIH R01NS065667, PI, 2008-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) BrightFocus Foundation (2) Cure Alzheimer's Fund (3) Association for Frontotemporal Degeneration (4) Rainwater Foundation (5) Alzheimer's Association (6) GHR Foundation (7) Foundation for Barnes Hospital
Stock/stock Options/board of Directors Compensation:
1.
C2N Diagnostics
License Fee Payments, Technology or Inventions:
1.
C2N Diagnostics, Washington University
Royalty Payments, Technology or Inventions:
1.
C2N Diagnostics, Washington University
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
for the Dominantly Inherited Alzheimer Network
From the Department of Neurology (E.M., J.H., V.B., A.M.F., D.M.H., J.C.M., K.P., R.J.B.), Division of Biostatistics (G.W., C.X.), Department of Radiology (B.A.G., T.L.S.B., D.S.M.), and Department of Pathology (N.J.C.), Washington University School of Medicine, Saint Louis, MO; Department of Neuroscience (A.M.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) (R.A.), Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina; University of Pittsburgh School of Medicine (S.B.B., W.K.), PA; College of Physicians and Surgeons (J.N.), Columbia University, New York, NY; Department of Neurology (J.R.), Keck School of Medicine of University of Southern California, Los Angeles; Department of Neurology (B.G., M.F.), Indiana University, Indianapolis; Massachusetts General Hospital (R.A.S., J.C.), Harvard Medical School, Boston; Butler Hospital and Brown University (S.S.), Providence, RI; Department of Neurology (N.R.G.-R.), Mayo Clinic Jacksonville, FL; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney; The Florey Institute and the University of Melbourne (C.M.), Parkville, Australia; Dementia Research Centre, Institute of Neurology (M.N.R., N.C.F.), University College London, UK; German Center for Neurodegenerative Diseases (DZNE) Munich (J.L.); Department of Neurology (J.L.), Ludwig-Maximilians Universität München; German Center for Neurodegenerative Diseases (DZNE) Tübingen (M.J.); and Hertie-Institute for Clinical Brain Research (M.J.), University of Tübingen, Germany.
Notes
Correspondence Dr. McDade [email protected] or Dr. Bateman [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Coinvestigators are listed at links.lww.com/WNL/A698.
Author Contributions
E.M., G.W., B.A.G., J.H., C.X., R.J.B.: data analysis, literature search, study design, writing. E.M., V.B., A.M.F., A.M.G., D.S.M., J.C.M., R.A., S.B.B., W.K., J.N., J.R., B.G., M.R., R.A.S., J.C., S.S., N.R.G.-R., P.R.S., M.N.R., N.C.F., J.L., M.J., R.J.B.: data collection. B.A.G., T.L.S.B., V.B., D.H., N.J.C., A.M.F., A.M.G., D.S.M., J.C.M., R.A., S.B.B., W.K., J.N., J.R., B.G., M.R., R.A.S., J.C., S.S., N.R.G.-R., P.R.S., M.N.R., N.C.F., J.L., M.J., R.J.B.: critical analysis of manuscript.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
-
- Ge Li,
- Jeffrey Iliff,
- Jane Shofer,
- Cynthia L. Mayer,
- James Meabon,
- David Cook,
- Kathleen F. Pagulayan,
- Murray A. Raskind,
- Henrik Zetterberg,
- Kaj Blennow,
- Elaine R. Peskind,
-
- Sean Commins,
- Antoine Coutrot,
- Michael Hornberger,
- Hugo J Spiers,
- Rafael De Andrade Moral,
-
- Mariana Pires,
- Ana Cristina Rego,
-
- Takeshi Kawarabayashi,
- Takumi Nakamura,
- Kazuya Miyashita,
- Tatsuya Segawa,
- Isamu Fukamachi,
- Takashi Sugawara,
- Hironori Oka,
- Kunihiko Ishizawa,
- Masakuni Amari,
- Hiroo Kasahara,
- Kouki Makioka,
- Yoshio Ikeda,
- Masamitsu Takatama,
- Mikio Shoji,
-
- María Pascual-Lucas,
- José Antonio Allué,
- Leticia Sarasa,
- Noelia Fandos,
- Sergio Castillo,
- Jose Terencio,
- Manuel Sarasa,
- Juan Pablo Tartari,
- Ángela Sanabria,
- Lluís Tárraga,
- Agustín Ruíz,
- Marta Marquié,
- Sang Won Seo,
- Hyemin Jang,
- Mercè Boada,
- N. Aguilera,
- E. Alarcón-Martín,
- M. Alegret,
- S. Alonso-Lana,
- M. Berthier,
- U. Bojayrin,
- M. Buendia,
- S. Bullich,
- F. Campos,
- A. Cano,
- P. Cañabate,
- L. Cañada,
- C. Cuevas,
- I. de Rojas,
- S. Diego,
- A. Espinosa,
- E. Esteban-De Antonio,
- A. Gailhajenet,
- A García-Sánchez,
- P. García,
- J. Giménez,
- M. Gómez-Chiari,
- M. Guitart,
- I. Hernández,
- M. Ibarria,
- A. Lafuente,
- N. Lleonart,
- F. Lomeña,
- E. Martín,
- M. Moreno,
- A. Morera,
- L. Montrreal,
- N. Muñoz,
- L. Narvaiza,
- A. Niñerola,
- A. B. Nogales,
- L. Núñez,
- A. Orellana,
- G. Ortega,
- A. Páez,
- A. Pancho,
- E. Pelejà,
- E. Pérez,
- A. Pérez-Cordon,
- A. Perissinotti,
- S. Preckler,
- V. Pytel,
- M. Ricciardi,
- O. Rodríguez-Gomez,
- N. Roé-Vellvé,
- M. I. Ramis,
- M. Rosende-Roca,
- S. Seguer,
- O. Sotolongo-Grau,
- A. Stephens,
- M. A. Tejero,
- M. Torres,
- S. Valero,
- L. Vargas,
- A. Vivas,
-
- Xianfeng Yu,
- Kai Shao,
- Ke Wan,
- Taoran Li,
- Yuxia Li,
- Xiaoqun Zhu,
- Ying Han,
-
- Kristina M. Gicas,
- William G. Honer,
- Vladislav A. Petyuk,
- Robert S. Wilson,
- Patricia A. Boyle,
- Sue E. Leurgans,
- Julie A. Schneider,
- Philip L. De Jager,
- David A. Bennett,
-
- Matías Nicolás Bossa,
- Hichem Sahli,
-
- Reddy Peera Kommaddi,
- Aditi Verma,
- Graciela Muniz-Terrera,
- Vivek Tiwari,
- Keerthana Chithanathan,
- Latha Diwakar,
- Ruturaj Gowaikar,
- Smitha Karunakaran,
- Palash Kumar Malo,
- Neill R. Graff-Radford,
- Gregory S. Day,
- Christoph Laske,
- Jonathan Vöglein,
- Georg Nübling,
- Takeshi Ikeuchi,
- Kensaku Kasuga,
- Vijayalakshmi Ravindranath,
-
- Yun Zhang,
- Huaqiu Chen,
- Ran Li,
- Keenan Sterling,
- Weihong Song,
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.
Purchase Access, $39 for 24hr of access